Exploring the EQ-5D dimension of pain/discomfort in dermatology outpatients from a multicentre study in 13 European countries
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- 5734
Forlagets udgivne version, 2,26 MB, PDF-dokument
Pain and discomfort are important symptoms in dermatology. The aim of this cross-sectional, multicentre study was to describe the prevalence of pain/discomfort and its associations in patients with several dermatological conditions across 13 European countries. The outcome was the prevalence of pain/discomfort according to a question of the EQ-5D questionnaire. Data collected from November 2011 to February 2013 were complete for 3,509 consecutive outpatients. Moderate or extreme pain/discomfort was reported by 55.5% of patients and 31.5% of controls with no skin conditions. The highest proportions were reported by patients with hidradenitis suppurativa (92.9%), leg ulcer (81.4%), prurigo (80%) and lichen planus (75.6%). Pain/discomfort was associated with older age, low educational level, clinical severity, flare on scalp or hands, itch, depression, anxiety, low quality of life, and thoughts of suicide. It is important to enquire specifically about pain/discomfort during clinical consultations and to address it when planning a patient’s care.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | adv00120 |
| Tidsskrift | Acta Dermato-Venereologica |
| Vol/bind | 100 |
| Udgave nummer | 8 |
| Sider (fra-til) | 1-6 |
| Antal sider | 6 |
| ISSN | 0001-5555 |
| DOI | |
| Status | Udgivet - 2020 |
Bibliografisk note
Funding Information:
ally supported by the “Progetto Ricerca Corrente RC 4.1” of the Italian Ministry of Health, Rome, Italy. FS acted as a consultant for Abbvie, Janssen, Eli Lilly, and Pierre Fabre; JS is a consultant and Advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Pharmaceuticals and Sandoz, Investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regereron, Takeda, Trevi, Speaker for AbbVie, Actavis, Astellas, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly; AYF is joint copyright owner of the DLQI, Cardiff University and AYF receive royalties, AYF is a member of a Novartis advisory board.
Funding Information:
sources and conflicts of interest: FS and DA are parti-ally supported by the ?Progetto Ricerca Corrente RC 4.1? of the Italian Ministry of Health, Rome, Italy. FS acted as a consultant for Abbvie, Janssen, Eli Lilly, and Pierre Fabre; JS is a consultant and Advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Pharmaceuticals and Sandoz, Investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regereron, Takeda, Trevi, Speaker for AbbVie, Actavis, Astellas, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly; AYF is joint copyright owner of the DLQI, Cardiff University and AYF receive royalties, AYF is a member of a Novartis advisory board.
Publisher Copyright:
© 2020 Acta Dermato-Venereologica.
ID: 271639866